By necessity New Zealanders are outward looking... well grounded but open to new ideas.

Investment New Zealand
   You are at: Home> News and Events > News Archive > New Zealand pioneers brain trauma treatment

New Zealand pioneers brain trauma treatment

01 August 2005

A recent article in the New Zealand Herald newspaper has highlighted a key example of the potential of the New Zealand biotechnology industry.

Pioneering New Zealand pharmaceutical company Neuren Pharmaceuticals is moving to Phase III clinical trials for its lead candidate, Glypromate, and Phase I for its second drug NNZ-2566.

Neuren has received accelerated approval for Glypromate, and NNZ-2566 is being developed in partnership with the US Walter Reed Army Institute of Research, in Silver Spring , Maryland.  The two new drugs have the potential to greatly reduce the effects of brain trauma. 

View the full NZ Herald article here: http://www.nzherald.co.nz/index.cfm?ObjectID=10335179

ˆPage Top  |  Reports & Publications  |  Contact Us

Search for:

Privacy Statement  |  Terms & Conditions  |  Site Feedback  |  Sitemap


Investment New Zealand is the investment promotion agency of the New Zealand government and a division of New Zealand Trade and Enterprise

Copyright © 2005-2009 New Zealand Trade and Enterprise